Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. - Wikidata - awgldk - TriplyDB

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

http://www.wikidata.org/entity/Q33596863

about

Cost impact of a non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service setting Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014 USING CLAIMS DATA FOR EVIDENCE GENERATION IN MANAGED ENTRY AGREEMENTS.Opportunities and challenges in leveraging electronic health record data in oncology.Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts The role of health technology assessment bodies in shaping drug development.Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces The use of risk sharing tools for post adoption surveillance of a non pharmacological technology in routine practice: results after one year.Personalizing health care: feasibility and future implications.Policies to enhance prescribing efficiency in europe: findings and future implications.Patient access schemes in Asia-pacific markets: current experience and future potential Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in bulgaria.International variability in the reimbursement of cancer drugs by publically funded drug programs Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.Discounts and rebates granted to public payers for medicines in European countries Reimbursement of licensed cell and gene therapies across the major European healthcare markets.Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.Health economic value of an innovation: delimiting the scope and framework of future market entry agreements.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.Routine real-time cost-effectiveness monitoring of a web-based depression intervention: a risk-sharing proposal.Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.Use of product listing agreements by Canadian provincial drug benefit plans.Product listing agreements (PLAs): a new tool for reaching Quebec's pharmaceutical policy objectives?Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.Market access of cancer drugs in European countries: improving resource allocation.Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices.The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Drug Pricing in South Korea.The intriguing future of pharmacoepidemiology.Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.

P2860

Q26779553-18E53DF7-B436-4FC4-A476-A5BAFEA260B0 Q27027259-24E82ECC-832C-4E2E-B5E9-EF74E1574D02 Q31058117-08A031E1-2F39-4E28-AE15-A6DBB1FC14BD Q31081502-8453152C-B513-4B11-824A-1AC175D8FAB0 Q33664087-7A7BBE0E-EA41-430E-933F-2E3F1122B594 Q33730353-58172859-4FE2-4D29-949C-0B22419DC63D Q33730376-A4119DF7-324D-4701-9AAC-DFC76D0C00DB Q34044177-415A2FA0-3692-4270-BA0D-45EE5A9FC8E0 Q34524056-E5062E57-33C2-4962-A24B-1D6BC354DEBA Q34567661-3A398E13-2D93-42A0-B6B1-2967D5215CBB Q34729037-5D985FCC-FDEB-4889-8D6A-FFF7CF1369C1 Q34938911-A667F1A6-FF70-47B2-8841-F0A391C1BEA0 Q35155250-342B348C-4F35-480C-A543-50F281B81AF2 Q35176587-3A33976B-5410-4BE6-BAC0-DA794E8E7195 Q35454428-E6C50A93-BCC4-4065-ADDC-B71203C7516A Q35522232-EB4BCB40-545E-4B3C-B37B-5197B2203FB7 Q36000247-483E2866-39A3-4676-980F-9F16B701B44A Q36110773-8FADA866-A911-4965-89FC-DC312B9E4633 Q36317043-A8D23FE1-B0E7-42EC-AC81-354FAFA464CB Q36714663-A9FD9910-4859-4083-B8DD-2AE9857D957C Q36841028-4568BD70-A046-4739-A78D-014AF8B9726D Q36897824-E0C2F482-DF52-40C6-B8CD-12920F24E039 Q37135584-B7D054D5-DCC5-4B76-9E59-B299C01CD4C9 Q37225782-F2601420-0ED8-4B3F-846A-7235883D6A25 Q37290101-D80CF458-2E95-4E70-A2F1-721B2250D7E9 Q37441285-0D604C2E-EEBE-4FB6-AAFD-FA195A24CEF5 Q37653487-E73D06B2-4122-4059-9BDD-AEAEF9FFEF4D Q37672032-7D0580E0-FBDA-4D45-9595-F8F3FACF7204 Q37723077-A0C4D8E4-B30D-44C5-96A0-93F2AE1608BD Q37723123-85A2E474-D6EA-4619-8DF8-DB2CCCF15605 Q38162866-BDEE9B1E-A9F6-454B-A3A9-CA63741B3E37 Q38163486-CB45F2B9-2D92-4FA4-8808-1624EA59CFD8 Q38175354-FBE1DB79-D56C-4A0F-8271-BB51A582F6A5 Q38223213-5CE6B9A5-20E0-43F6-9BE3-4DE0DC0E81B9 Q38610858-343CA052-A53D-4ABE-A562-A50D230186C6 Q38954063-155E0422-5460-4432-95C8-F5470CE751A0 Q39072439-AFFEDD55-D104-4E62-A401-D491EA0AFD4A Q39110814-5E99482D-AF6E-44FA-9989-62D1692977CB Q39422831-BDA47AB9-940D-4E43-B152-616A83BBC3D5 Q39432116-220169EC-2E91-4B6B-B0B1-2D3A1AE84E65

P2860

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

http://www.wikidata.org/entity/Q33596863

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Risk sharing arrangements for ...... endations for European payers.

@ast

Risk sharing arrangements for ...... endations for European payers.

@en

type

label

Risk sharing arrangements for ...... endations for European payers.

@ast

Risk sharing arrangements for ...... endations for European payers.

@en

prefLabel

Risk sharing arrangements for ...... endations for European payers.

@ast

Risk sharing arrangements for ...... endations for European payers.

@en

P1433

Q33596863-E756CFBB-1941-4A1C-99CF-3684CF979D7B

P1476

Q33596863-05431021-681A-4017-A4B3-4BD1E4559152

P2093

Q33596863-088BBA7C-BB6E-4C7E-AA59-E1DD4A3F532D

Q33596863-0AEB2B61-3A2B-4B88-A56C-400F2869A4C2

Q33596863-4D58AC91-F7BD-4E14-809F-D007AECD826E

Q33596863-54311C02-CDF0-4DE4-AD93-C9D7EF0CB092

Q33596863-658FE384-631D-4C39-AE29-3FA1063486EB

Q33596863-8BC2EAA1-8C6A-4583-B807-F13C10BBC4B4

Q33596863-9E9197FF-384E-4B0B-B3B1-0E63F1A7C9DA

Q33596863-A68AC928-8128-4DCC-B6DE-E35B2FA58FD5

Q33596863-AFA75988-4610-445A-BD60-82BBAEF80996

Q33596863-BEF76E98-DE27-4862-A749-D465950D2DB1

P2860

Q33596863-0412F2F8-23C2-487E-9095-6CD43BFAE72E

Q33596863-04663B72-5E74-43D2-A857-6881CDA16FAA

Q33596863-10CAA73D-3975-4F47-BFDB-A921B584C2CE

Q33596863-1338DC12-C1E6-4651-91A9-25BA4E6EB2F1

Q33596863-13BE6F8E-4F98-42B9-9F67-7C794DC0041D

Q33596863-29553534-7B3B-49B8-9807-7E669016E5DE

Q33596863-2C3F20CA-71E1-4686-890B-F6BC05101A78

Q33596863-2D1FF171-E2E4-4BEC-B530-895FF4529BA5

Q33596863-372CF392-2330-4FBF-BC28-B67C7C5259B0

Q33596863-3BCBBE3B-C923-4DA7-A1B8-A9C359077E33

P2888

Q33596863-6EB3C564-8B09-4495-A2D1-6DF8E016406A

P304

Q33596863-58332926-A7E7-45C0-91C6-612C7455C4B5

P31

Q33596863-A18D3374-3F86-43ED-9E8C-36803A71EB8C

P356

Q33596863-9D20A5F1-666E-4074-981E-25401F2BED3F

P478

Q33596863-DF095515-FCE1-41D4-892F-4CFFB2F476E2

P50

Q33596863-73A4424F-D860-47D6-9A80-6A6FDF17BD94

P577

Q33596863-4B5F69A2-9FFC-4256-9057-944260438365

P5875

Q33596863-8FC6EB75-D0DD-40FE-93CF-0071263ACC38

P6179

Q33596863-4CC2049E-E207-46F5-A264-C240A38CEFA0

P698

Q33596863-F4B19106-BCD7-4254-8AA9-B5AD74F2028E

P932

Q33596863-84B6C874-1922-4E35-B906-E4244DA85EA9

P356

1472-6963-10-153

P1433

BMC Health Services Research

P1476

Risk sharing arrangements for ...... endations for European payers.

@en

P2093

Alan Haycox

http://www.w3.org/2001/XMLSchema#string

Bogusława Osińska

http://www.w3.org/2001/XMLSchema#string

Brian Godman

http://www.w3.org/2001/XMLSchema#string

Catherine Sermet

http://www.w3.org/2001/XMLSchema#string

Corrine Zara

http://www.w3.org/2001/XMLSchema#string

Gabriella Ofierska-Sujkowska

http://www.w3.org/2001/XMLSchema#string

Harald Herholz

http://www.w3.org/2001/XMLSchema#string

Jakub Adamski

http://www.w3.org/2001/XMLSchema#string

Kamila Wendykowska

http://www.w3.org/2001/XMLSchema#string

Kristina Garuolienè

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmaceutical policies: effects of financial incentives for prescribers

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care.

How much will Herceptin really cost?

How can we regulate medicines better?

No cure, no pay.

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures.

Value based pricing for NHS drugs: an opportunity not to be missed?

P2888

1472-6963-10-153

P304

153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1472-6963-10-153

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Lars L. Gustafsson

P577

2010-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

202314971

http://www.w3.org/2001/XMLSchema#string

P6179

1049104756

http://www.w3.org/2001/XMLSchema#string

P698

20529296

http://www.w3.org/2001/XMLSchema#string

P932

2906457

http://www.w3.org/2001/XMLSchema#string